What is the therapy of bisphosphonate?

Bisphosphonate therapy is the use of chemical class bisphosphonates to treat osteoporosis and other conditions involving bone loss. They are mainly used in women who have undergone menopause and suffered bone loss. Some of these drugs are also used to treat other diseases that cause bone mass, such as Paget's disease and multiple myeloma. These drugs cause the death of cells that cause the dissolution of bone compounds during the disintegration process and bone conversion. These processes usually work as well, resulting in a strong bone. In menopause, however, this process can move in the direction of bone decay, resulting in a fragile bone that easily breaks. This loss of bone mass is known as osteoporosis and is commonly treated with bisphosphonate therapy.

Many compounds are considered. They all have two phosphonate, after _{3 , units associated with carbon spine. This structural function classifies it as a diffosphonate. Central carbon is wearingTwo side chains that differ in the structure. These side chains are what determines the specificity and chemical properties of different drugs.}

The main difference between compounds used in bisphosphonate therapy is whether nitrogen groups have on a long side chain. Commonly prescribed drugs of ibandronate and alendronate have nitrogen. These drugs are widely prescribed to women who have undergone scanning of bone density and have been diagnosed with osteoporosis or other condition that causes bone loss

bones are the main source of calcium in the body. All of these compounds are firmly weighing on the calcium. They almost completely bind to the bones. About 50% of the bisphosphonates are excreted in the urine.

It has been shown that bisphosphonate therapy with Alendronate and ibandronate increases bone mass and helps to improve the health of patients with osteoporosis in use for five years. It is not clear whether it will be mLonger benefits for patients. The pills should be used with a specific amount of water to prevent esophageal irritation, and the patient should also remain upright for 60 minutes after the dose.

These compounds can remain in the body for years. They can cause abnormalities in the developing fetus, so it is strongly recommended that pregnant women do not take these drugs. Young women are also advised to avoid these drugs. Food and drug management (FDA) in the United States in 2010 issued a statement that the occurrence of a rare type of fracture in the femur or femur may be increased in women who have undergone bisphosphonate therapy for a long time.